Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 8/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.64 |
| ▸ | GAA | P10253 | 6/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | IDO1 | P14902 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10340526 | 0.81 | L3MBTL1 (0.71) | SMN1; SMN2L3MBTL1MAPTALDH1A1GAA | |
| SCHEMBL7175227 | 0.81 | MAPT (0.86) | SMN1; SMN2L3MBTL1MAPTALDH1A1GAA | |
| SCHEMBL12337052 | 0.81 | MAPT (0.58) | SMN1; SMN2L3MBTL1MAPTALDH1A1GAA | |
| SCHEMBL22567938 | 0.80 | MAPT (0.78) | SMN1; SMN2L3MBTL1MAPTALDH1A1GAA | |
| Iodide SCHEMBL10827355 | 0.79 | MAPT (0.56) | SMN1; SMN2L3MBTL1MAPTALDH1A1GAA | |
| SCHEMBL5448283 | 0.79 | SMN1; SMN2 (1.00) | SMN1; SMN2L3MBTL1MAPTALDH1A1GAA | |
| SCHEMBL12412637 | 0.79 | ALDH1A1 (0.76) | SMN1; SMN2L3MBTL1MAPTALDH1A1GAA | |
| SCHEMBL12336440 | 0.78 | MAPT (0.55) | SMN1; SMN2L3MBTL1MAPTALDH1A1GAA | |
| SCHEMBL20560252 | 0.78 | MAPT (0.70) | SMN1; SMN2L3MBTL1MAPTALDH1A1GAA | |
| SCHEMBL230618 | 0.78 | IDO1 (0.71) | SMN1; SMN2L3MBTL1MAPTALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368454-B2 | serotonin receptor modulator; antidepressant, anxiolytic agent; drug abuse; schizophrenia | HOFFMANN-LA ROCHE INC. (US) | 2008-05-06 | — | — | US | disclosed |
| EP-1861102-A1 | USE OF 2-ANILINO-3,4-DIHYDRO-QUINAZOLINES AS 5HT5A RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| US-20060211716-A1 | (3,4-Dihydro-quinazolin-2-yl)-aryl-amines | F. HOFFMAN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-09-21 | — | — | US | disclosed |
| WO-2006097391-A1 | USE OF 2 -ANILINO - 3 , 4 -DIHYDRO - QUINAZOLINES AS 5HT5A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211716-A1 | (3,4-Dihydro-quinazolin-2-yl)-aryl-amines | HTR5A, HTR1A, HTR2C | SMN1; SMN2 1447/4885L3MBTL1 4464/4885MAPT 3022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.